Blazar™ Platform
Established in 1963, the R&D 100 Awards is the only S&T (science and technology) awards competition that recognizes new commercial products, technologies and materials for their technological significance that are available for sale or license. The R&D 100 Awards have long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology.
This year's R&D 100 2020 winner is listed below in their respective category.
Category: Analytical/Test
Developers: MilliporeSigma
United States
Product Description:As the drug manufacturing process evolves, rapid testing will become an essential component in intensified processing and how the industry will detect adventitious agents. MilliporeSigma has developed a first-of-its-kind assay platform that provides highly sensitive viral detection in just days. The innovative Blazar Platform reduces turn-around-time from up to 63 days to ten days, while testing for 25 additional and emerging viral risks not covered in current guidance. Providing faster cell line characterization will help biopharmaceutical manufacturers maintain competitiveness, reduce bottlenecks and keep critical development timelines on track. In addition to these industry benefits, this platform provides a significant step towards removing animal usage from the biosafety testing of biologics. MilliporeSigma has developed a rodent virus panel for the BioReliance Blazar platform. This rodent virus panel provides a suitable alternative to the current in vivo MAP/HAP/RAP test that eliminates the need for animals.
Developers: MilliporeSigma
United States
Product Description:As the drug manufacturing process evolves, rapid testing will become an essential component in intensified processing and how the industry will detect adventitious agents. MilliporeSigma has developed a first-of-its-kind assay platform that provides highly sensitive viral detection in just days. The innovative Blazar Platform reduces turn-around-time from up to 63 days to ten days, while testing for 25 additional and emerging viral risks not covered in current guidance. Providing faster cell line characterization will help biopharmaceutical manufacturers maintain competitiveness, reduce bottlenecks and keep critical development timelines on track. In addition to these industry benefits, this platform provides a significant step towards removing animal usage from the biosafety testing of biologics. MilliporeSigma has developed a rodent virus panel for the BioReliance Blazar platform. This rodent virus panel provides a suitable alternative to the current in vivo MAP/HAP/RAP test that eliminates the need for animals.
Blazar Platform